Skip to main content

Table 2 Univariate and multivariate analysis of overall survival based on clinical and molecular variables

From: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

VariableUnivariate analysisMultivariate analysis
Crude HR95%CIPAdjusted HR95%CIP
Age1.021.00–1.030.021.011.00–1.030.07
Sex
 Female1  1  
 Male1.411.05–1.900.021.080.74–1.580.71
Ever Smoking
 Non-smoker1  1  
 Smoker1.461.13–1.900.0041.391.00–1.940.05
Pathology
 Adenocarcinoma1     
 Squamous carcinoma1.160.71–1.880.55   
 others1.140.64–2.060.65   
Stage
 I-II1  1  
 III1.550.88–2.740.131.580.89–2.810.12
 IV2.681.60–4.47***2.721.62–4.56***
KRAS mutation
 Wildtype1  1  
 Mutation1.511.16–1.980.0031.300.98–1.720.07
KRAS mutation subtype
 Wild-type1  1  
G12C mutation1.651.10–2.470.021.470.97–2.230.07
 Non-G12C mutation1.451.06–1.980.021.230.90–1.690.20
  1. NSCLC non-small cell lung cancer, HR hazard ratio